INBX News
Wednesday 9/9 Insider Buying Report: INBX, AMR
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
At Inhibrx Biosciences, a filing with the SEC revealed that on Tuesday, Chief Execu...
Nasdaq News: Markets
Wednesday 9/9 Insider Buying Report: INBX, AMR
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
At Inhibrx Biosciences, a filing with the SEC revealed that on Tuesday, Chief Execu...
Nasdaq News: Markets
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.read more...
Benzinga
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study PR Newswire SAN DIEGO, Sept. 8, 2026 First OX40 agonist to...
PR Newswire
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study PR Newswire SAN DIEGO, Sept. 4, 2026 Event to be webcast live...
PR Newswire
Inhibrx Reports Second Quarter 2026 Financial Results
Inhibrx Reports Second Quarter 2026 Financial Results Inhibrx Reports Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, Aug. 13, 2026 SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the...
PR Newswire
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million PR Newswire SAN DIEGO, July 16, 2026 SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx...
PR Newswire
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma PR Newswire SAN DIEGO, June 15, 2026 No filing review issues identified by FDA with PDUFA...
PR Newswire
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Reports First Quarter 2026 Financial Results Inhibrx Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx...
PR Newswire
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study...
Yahoo! Finance: News